{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:54:44Z","timestamp":1776092084538,"version":"3.50.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.tmrv.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T02:02:28Z","timestamp":1661652148000},"page":"220-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapies in Autoimmune Peripheral Neuropathies beyond Intravenous Immunoglobulin, Plasma Exchange and Corticosteroids: An Analytical Review"],"prefix":"10.1016","volume":"36","author":[{"given":"Ajith","family":"Sivadasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2022.05.002_bib0001","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0002","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1212\/CON.0000000000000513","article-title":"Guillain-Barr\u00e9 Syndrome","volume":"23","author":"Donofrio","year":"2017","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0003","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1468-1331.2009.02802.x","article-title":"Italian Network for CIDP Register. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"17","author":"Cocito","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0004","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1529-8027.2010.00251.x","article-title":"A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"15","author":"Viala","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0005","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/immuno2010009","article-title":"CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention","volume":"2","author":"Brun","year":"2022","journal-title":"Immuno"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0006","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0007","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12974-017-1001-8","article-title":"Novel pathomechanisms in inflammatory neuropathies","volume":"14","author":"Schafflick","year":"2017","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0008","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.mayocp.2016.12.002","article-title":"Guillain-Barr\u00e9 Syndrome","volume":"92","author":"Wijdicks","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0009","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2007.11.017","article-title":"Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barr\u00e9 syndrome","volume":"194","author":"Jacobs","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/jnnp-2017-317192","article-title":"Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground","volume":"89","author":"Uncini","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0011","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1016\/j.clinph.2018.09.025","article-title":"The electrodiagnosis of Guillain-Barr\u00e9 syndrome subtypes: Where do we stand?","volume":"129","author":"Uncini","year":"2018","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0012","series-title":"Clinical immunology: Principles and practice","first-page":"977","article-title":"Autoimmune peripheral neuropathies","author":"Dalakas","year":"2011"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0013","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.tmrv.2022.05.002_bib0014","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1007\/s10875-010-9407-4","article-title":"IVIG treatment and prognosis in Guillain-Barr\u00e9 syndrome","volume":"30 Suppl 1","author":"van Doorn","year":"2010","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2058739220942340","article-title":"Inflammatory polyradiculoneuropathies: Clinical and immunological aspects, current therapies, and future perspectives","volume":"18","author":"Di Stefano","year":"2020","journal-title":"Eur J Inflamm"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0016","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jnnp.54.11.957","article-title":"Treatment related fluctuations in Guillain-Barr\u00e9 syndrome after high-dose immunoglobulins or plasma-exchange","volume":"54","author":"Kleyweg","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0017","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0018","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/mus.21480","article-title":"Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy","volume":"41","author":"Dionne","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001798.pub2","article-title":"Plasma exchange for Guillain-Barr\u00e9 syndrome","volume":"7","author":"Rapha\u00ebl","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0020","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/B978-0-323-71317-7.00015-9","article-title":"15 - Treatment and Management of Autoimmune Neuropathies","author":"El-Abassi","year":"2022","journal-title":"Neuromuscular Disorders (Second Edition)"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0021","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2016-314862","article-title":"Treatment dilemmas in Guillain-Barr\u00e9 syndrome","volume":"88","author":"Verboon","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0022","doi-asserted-by":"crossref","first-page":"e27351","DOI":"10.1097\/MD.0000000000027351","article-title":"Efficacy of therapies in the treatment of Guillain-Barre syndrome: A network meta-analysis","volume":"100","author":"Lin","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0023","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome","volume":"6","author":"van Koningsveld","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2019-321496","article-title":"IGOS Consortium. Original research: Second IVIg course in Guillain-Barr\u00e9 syndrome with poor prognosis: the non-randomised ISID study","volume":"91","author":"Verboon","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Dutch GBS Study Group. Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0026","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0027","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","article-title":"Inhibition of complement in Guillain-Barr\u00e9 syndrome: the ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0028","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Japanese Eculizumab Trial for GBS (JET-GBS) Study Group. Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231892","article-title":"Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5","volume":"15","author":"Latuszek","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0030","unstructured":"A Clinical Study of ANX005 and IVIG in Subjects with Guillain Barre Syndrome (GBS). Available online at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04035135 (accessed March 27th, 2022)"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0031","unstructured":"A Study of Imlifidase in Patients With Guillain-Barre Syndrome. Available online at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03943589 (accessed March 27th, 2022)"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0032","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr\u00e9 syndrome","volume":"1","author":"Doets","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0033","unstructured":"A Clinical Trial of CK0801 (A New Drug) in patients with Treatment-Resistant Guillain Barre Syndrome. Available online at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03773328 (accessed March 27th, 2022)"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0034","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.intimp.2018.06.015","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with Bifidobacterium infantis through regulation of T helper cells subsets","volume":"61","author":"Shi","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","article-title":"Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP","volume":"7","author":"Dalakas","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0036","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bbadis.2014.06.013","article-title":"Pathogenesis of immune-mediated neuropathies","volume":"1852","author":"Dalakas","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0037","series-title":"Clinical immunology: principles and practice","first-page":"977","article-title":"Autoimmune peripheral neuropathies","author":"Dalakas","year":"2011"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0038","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archneur.1980.00500590061010","article-title":"Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy","volume":"37","author":"Dalakas","year":"1980","journal-title":"Arch Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104205","article-title":"Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes","volume":"9","author":"Shimizu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.semcdb.2017.06.009","article-title":"Molecular cell biology of complement membrane attack","volume":"72","author":"Morgan","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0041","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/cei.12756","article-title":"Regulatory T and B lymphocytes in a spontaneous autoimmune polyneuropathy","volume":"184","author":"Quan","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0042","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"82","author":"Querol","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0043","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.23794","article-title":"Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Querol","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0044","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/brain\/awx124","article-title":"Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy","volume":"140","author":"Delmont","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0045","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jns.12237","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components","volume":"22","author":"ASBURY LECTURE","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0046","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1038\/s41598-017-14853-4","article-title":"Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"7","author":"Querol","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0047","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/acn3.248","article-title":"Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy","volume":"2","author":"Ogata","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0048","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0049","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"PATH study group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"van Schaik","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0050","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1212\/NXI.0000000000000590","article-title":"PATH study group. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study","volume":"6","author":"Van Schaik","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0051","unstructured":"Long term Tolerability and Safety of HYQVIA\/HyQvia in CIDP. Available online at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02955355 (accessed on 27th March 2022)"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0052","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: principles, evidence and practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Pract Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0053","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s00415-021-10646-y","article-title":"Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"269","author":"Hu","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0054","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jns.12287","article-title":"Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases","volume":"23","author":"Roux","year":"2018","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0055","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.26804","article-title":"Rituximab in refractory chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Muley","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0056","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421999631","article-title":"Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study","volume":"14","author":"Motte","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0057","doi-asserted-by":"crossref","first-page":"e17117","DOI":"10.2196\/17117","article-title":"Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial","volume":"9","author":"Shimizu","year":"2020","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0058","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0059","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/ene.14498","article-title":"Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies","volume":"27","author":"Casertano","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0060","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0061","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0062","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s00415-017-8599-4","article-title":"Severe refractory CIDP: a case series of 10 patients treated with bortezomib","volume":"264","author":"Pitarokoili","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0063","article-title":"Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews","volume":"1","author":"Oaklander","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0064","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.35.8.1173","article-title":"Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy","volume":"35","author":"Dyck","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1474-4422(08)70299-0","article-title":"Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study","volume":"8","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0066","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"FORCIDP Trial Investigators. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0067","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.nmd.2019.06.010","article-title":"Chronic inflammatory demyelinating polyneuropathy: Plasmapheresis or cyclosporine can be good treatment options in refractory cases","volume":"29","author":"Kim","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0068","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-009-5437-3","article-title":"Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy","volume":"257","author":"Marsh","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603237","article-title":"Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?","volume":"11","author":"Sadeqi Nezhad","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0070","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-021-01175-7","article-title":"Neonatal Fc Receptor-Targeted Therapies in Neurology","author":"Nelke","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0071","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.3390\/ijms22115755","article-title":"Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis","volume":"22","author":"Keller","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0072","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"ADAPT Investigator Study Group. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0073","unstructured":"A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE). Available online at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04281472 (accessed on 27th March, 2022)"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0074","series-title":"American Academy of Neurology Annual Meeting","article-title":"RVT-1401, A novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration. (P5.2\u2013079)","author":"Collins","year":"2019"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0075","unstructured":"Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Available online at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04658472 (accessed on 27th March, 2022)"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0076","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp.72.1.127","article-title":"Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy","volume":"72","author":"Vermeulen","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0077","first-page":"760","article-title":"Autologous Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy","volume":"48","author":"Masson-Roy","year":"2021","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0078","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.3389\/fimmu.2018.02602","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: from mechanistic insights to biomarkers","volume":"9","author":"Malmegrim","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0079","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1007\/s00415-020-10010-6","article-title":"Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"267","author":"Burt","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaut.2018.05.009","article-title":"An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies","volume":"92","author":"Brun","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0081","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40364-019-0154-2","article-title":"Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy","volume":"7","author":"Khoo","year":"2019","journal-title":"Biomark Res"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0082","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/jnnp-2019-321532","article-title":"Multifocal motor neuropathy: controversies and priorities","volume":"91","author":"Yeh","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0083","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/mus.25409","article-title":"Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis","volume":"55","author":"Racosta","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0084","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/mus.25107","article-title":"Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy","volume":"54","author":"Katzberg","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0085","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0b013e3181f735ce","article-title":"Long-Term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"75","author":"Harbo","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0086","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/ene.13978","article-title":"Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"26","author":"Al-Zuhairy","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0087","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","article-title":"Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial","volume":"16","author":"Harbo","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0088","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/jnnp.63.6.765","article-title":"Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy","volume":"63","author":"Meucci","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0089","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/brain\/awm144","article-title":"Van den Berg L. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial","volume":"130","author":"Piepers","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1529-8027.2010.00270.x","article-title":"An open-label trial of rituximab (Rituxan\u00ae) in multifocal motor neuropathy","volume":"15","author":"Chaudhry","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0091","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0092","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0093","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617746640","article-title":"Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0094","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"10","author":"Lunn","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0095","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0096","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"RIMAG Study Group (France and Switzerland). Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"L\u00e9ger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0097","article-title":"From biology to clinical management","volume":"361","author":"neuropathy","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0098","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1212\/NXI.0000000000000460","article-title":"Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy","volume":"5","author":"Rakocevic","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0099","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0100","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1212\/NXI.0000000000000720","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy","volume":"7","author":"Castellani","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0101","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.CON.0000455882.83803.72","article-title":"Acquired immune axonal neuropathies","volume":"20","author":"Bril","year":"2014","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.tmrv.2022.05.002_bib0102","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.610585","article-title":"Immune Axonal Neuropathies Associated With Systemic Autoimmune Rheumatic Diseases","volume":"12","author":"Tulb\u0103","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:19:59Z","timestamp":1760138399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796322000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0887796322000359"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.05.002","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapies in Autoimmune Peripheral Neuropathies beyond Intravenous Immunoglobulin, Plasma Exchange and Corticosteroids: An Analytical Review","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}